
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At‑Risk Individuals</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At‑Risk Individuals</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: <em>Gastroenterology</em> 2025  </li>
<li style="margin-left: 0px;">Topic: HBV reactivation risk management  </li>
<li style="margin-left: 0px;">Author(s): Faisal S. Ali et al.</li>
</ul>
<details><summary><strong>Part 1 – Foundations &amp; Methodology  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>1. Background &amp; Aims  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">HBVr occurs after immune‑modulating exposures.  </li>
<li style="margin-left: 0px;">Antiviral prophylaxis can mitigate HBVr risk.  </li>
<li style="margin-left: 0px;">Monitoring alone may suffice for select low‑risk cases.  </li>
</ul>
</div></details>
<details><summary><strong>2. Guideline Development Process  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Used GRADE framework to assess evidence.  </li>
<li style="margin-left: 0px;">Systematic review identified studies since 2014 version.  </li>
<li style="margin-left: 0px;">Evidence‑to‑Decision (EtD) considered benefits, harms, values, costs, equity.  </li>
</ul>
</div></details>
<details><summary><strong>3. Target Population &amp; Scope  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Frontline clinicians caring for at‑risk adults.  </li>
<li style="margin-left: 0px;">Includes patients on immunosuppressive drugs, biologics, and interventional therapies.  </li>
</ul>
</div></details>
<details><summary><strong>4. Evidence Review Highlights  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Identified 12 RCTs comparing prophylaxis vs monitoring.  </li>
<li style="margin-left: 0px;">Pooled relative risk (RR) for HBVr with prophylaxis = 0.18 (95% CI 0.11–0.30).  </li>
<li style="margin-left: 0px;">Baseline HBVr risk stratified: low &lt;1%, moderate 1‑10%, high &gt;10%.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>Part 2 – Risk Stratification &amp; Recommendations  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>5. High‑Risk Exposures (baseline &gt;10%)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Anthracycline derivatives in HBsAg‑positive patients → <strong>HIGH</strong> risk.  </li>
<li style="margin-left: 0px;">B‑cell depleting agents (rituximab, ofatumumab) → <strong>HIGH</strong> risk regardless serology.  </li>
<li style="margin-left: 0px;">Anti‑TNF agents in HBsAg‑positive individuals → <strong>HIGH</strong> risk.  </li>
</ul>
</div></details>
<details><summary><strong>6. Moderate‑Risk Exposures (1%–10%)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">B‑cell depleting agents in HBsAg‑negative/anti‑HBc⁺ patients → <strong>MODERATE</strong> risk.  </li>
<li style="margin-left: 0px;">Anti‑IL6, cytokine/integrin inhibitors in HBsAg‑positive → <strong>HIGH</strong>; in anti‑HBc⁺ → <strong>MODERATE</strong>.  </li>
<li style="margin-left: 0px;">CAR‑T therapy in HBsAg‑negative/anti‑HBc⁺ patients → <strong>MODERATE</strong> risk.  </li>
</ul>
</div></details>
<details><summary><strong>7. Low‑Risk Exposures (&lt;1%)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Methotrexate, azathioprine, 6‑MP monotherapy → <em>baseline</em> risk &lt; 1%.  </li>
<li style="margin-left: 0px;">Intra‑articular steroid injections → <em>low</em> HBVr risk.  </li>
<li style="margin-left: 0px;">Anti‑TNF agents in HBsAg‑negative/anti‑HBc⁺ patients → <strong>LOW</strong> risk.  </li>
</ul>
</div></details>
<details><summary><strong>8. Evidence‑Based Recommendations Overview  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Strong recommendation: antiviral prophylaxis for high‑risk individuals (moderate certainty).  </li>
<li style="margin-left: 0px;">Conditional recommendation: prophylaxis for moderate‑risk individuals (moderate certainty).  </li>
<li style="margin-left: 0px;">Conditional recommendation: monitoring alone for low‑risk individuals (moderate certainty).  </li>
</ul>
</div></details>
</div></details>
</div></details>
<details><summary><strong>AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At‑Risk Individuals</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: <em>Gastroenterology</em> 2025  </li>
<li style="margin-left: 0px;">Topic: HBV reactivation risk management  </li>
<li style="margin-left: 0px;">Author(s): Faisal S. Ali et al.</li>
</ul>
<details><summary><strong>Part 3 – Recommendations, Implementation &amp; Clinical Implications  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>9. Recommendation 1 – High‑Risk Prophylaxis (Strong)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Antiviral prophylaxis favored over monitoring alone.  </li>
<li style="margin-left: 0px;">Initiate antivirals <strong>before</strong> risk‑imposing therapy start.  </li>
<li style="margin-left: 0px;">Continue ≥6 months after exposure cessation; B‑cell agents → at least 12 months.  </li>
</ul>
</div></details>
<details><summary><strong>10. Recommendation 2 – Moderate‑Risk Strategy (Conditional)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Conditional prophylaxis favored over monitoring alone.  </li>
<li style="margin-left: 0px;">Patients valuing <em>avoiding long‑term antivirals</em> may choose active monitoring.  </li>
<li style="margin-left: 0px;">Monitoring interval: <strong>1‑to‑3 month</strong> visits, include HBV‑DNA &amp; ALT assessments.  </li>
</ul>
</div></details>
<details><summary><strong>11. Recommendation 3 – Low‑Risk Management (Conditional)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Suggest monitoring alone for baseline risk &lt; 1%.  </li>
<li style="margin-left: 0px;">Prophylaxis optional if patients prioritize <em>avoiding reactivation</em> over medication burden.  </li>
</ul>
</div></details>
<details><summary><strong>12. Recommendation 4 – Universal HBV Testing (Strong)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Test all at‑risk individuals per CDC guidance: HBsAg, anti‑HBs, total anti‑HBc.  </li>
<li style="margin-left: 0px;">No longer stratify screening by exposure magnitude.  </li>
<li style="margin-left: 0px;">Positive serology triggers baseline risk assessment &amp; management algorithm.  </li>
</ul>
</div></details>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
